Navigation Links
N30 Pharma Initiates Phase 1 Trials of Novel Reductase Inhibitor
Date:9/8/2010

BOULDER, Colo., Sept. 8 /PRNewswire/ -- N30 Pharmaceuticals, LLC today announced it has dosed the first human subject with N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR).

N6022 is the first GSNOR inhibitor to be administered to human beings. N6022 has the potential to be an important new treatment for acute exacerbations of human diseases, such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD) and other inflammatory conditions.

About N6022 N6022 is the lead product in N30 Pharma's portfolio of drugs which are designed to treat asthma, COPD and IBD. The initial Phase 1 testing in healthy subjects is designed to evaluate the safety, tolerability and pharmacokinetics of single, increasing intravenous dosages of N6022.  Data from this first-in-man trial will provide important safety, pharmacokinetic, and biomarker information on which to base the design of subsequent trials of N6022 as well as the development of reductase dosage forms suitable for chronic administration.

Targeting GSNORGSNOR breaks down s-nitrosoglutahione (GSNO), reducing the body's pool of GSNO.  In the lung, GSNO likely plays an important role in maintaining normal respiratory function through its influence on bronchial tone and anti-inflammatory effects.   Similarly, in the gut GSNO supports barrier function and maintains the integrity of the gut surface. In asthmatics, GSNOR upregulation and decreased GSNO levels have been shown to contribute to respiratory disease, and genetic variants of GSNOR have been correlated with disease susceptibility and poor response to therapy.  GSNO has also been found to be important in the cardiovascular system as well as the control of breathing.

About inhibitors of GSNORN30 Pharma's portfolio of proprietary compounds provides a platform of potent, selective and reversible inhibitors of GSNOR. They increase levels of GSNO, a s-nitrosothi
'/>"/>

SOURCE N30 Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. MAP Pharmaceuticals Reports No Difference in Pulmonary Artery Pressure Between LEVADEX™ and Placebo in Pharmacodynamics Trial
2. Isis Pharmaceuticals to Present at the Stifel Nicolaus 2010 Healthcare Conference
3. MAP Pharmaceuticals Announces All Non-Asthmatic Patients Complete Treatment in Open-Label Trial and Completion of Treatment in QT Trial for LEVADEX™ Clinical Program
4. Abbott Completes Acquisition of Piramals Healthcare Solutions Business, Becomes Leading Pharmaceutical Company in India
5. Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010
6. Supreme Court of Israel Rules in Favor of Sun Pharma
7. Cadence Pharmaceuticals to Present at Four Investment Conferences During the Month of September 2010
8. Pharmacy Franchise Owners Association Taps David Mayper as Executive Director
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Mylan Completes Acquisition of Bioniche Pharma Sooner Than Expected
11. Reportlinker Adds US Pharmaceutical Packaging Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014  Today DePuy ... new variable angle plating systems featuring its proprietary ... can adapt screw trajectory to match patient anatomy ... fragments of bone. The systems are being introduced ... Ankle Society (AOFAS) and the International Federation of ...
(Date:9/19/2014)... , Sept. 19, 2014 /PRNewswire-iReach/ -- ... to 2020″, provides key market data ... devices market. The report provides value, ... volume (in units) within market categories ... Sigmoidoscopes, Esophagoscopes & Gastroscopes, Duodenoscopes, Laparoscopes, ...
(Date:9/19/2014)... TRIANGLE PARK, N.C. , Sept. 19, 2014 ... focused on cloud-based drug design and development, partnering ... The company,s mission is to design new drugs ... 1 and 2 partners to further their development. ... its portfolio investments. To support this business model, ...
Breaking Medicine Technology:DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2
... C onsiderably higher risk of follicular lymphoma-related death in ... waxing and waning progression of disease , , ... ( NCCC ) recently ... lymphoma in California. , , Although survival rates ...
... , , , CAPE TOWN, ... today at the 5(th) International AIDS Society Conference from ARTEN ( ... and E mtricitabine [Truvada(R)] versus N evirapine). ARTEN is ... the first large study to directly compare the efficacy and safety ...
Cached Medicine Technology:Northern California Cancer Center's First-of-Its-Kind Research Reveals Low Socioeconomic Status Often Equals Poor Chance of Lymphoma Survival 2New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed 2New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed 3New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed 4New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed 5New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed 6
(Date:9/20/2014)... September 21, 2014 Weight Destroyer ... by fitness expert Michael Wren that has already helped ... and reverse health conditions like high blood pressure, high ... Shane Michaels, prompting an investigative review. , “Weight ... tips upside down by showing people what is truly ...
(Date:9/20/2014)... September 21, 2014 Increases in ... to greater waste treatment volumes. However, government regulations ... waste from landfill. According to IBISWorld industry analyst ... implemented strategies aimed at reducing the volume of ... recycled and recovered.” Still, a large proportion of ...
(Date:9/20/2014)... The print component of “Work-Life Balance” is being ... with a circulation of approximately 97,000 copies and ... is distributed nationally through a vast social media ... sites and partner outlets. To explore the digital ... , The publication features an exclusive Mediaplanet interview ...
(Date:9/20/2014)... Ticket Down is a reputable source ... 2015 “Honeymoon Tour.” This well-known ticket exchange is offering ... In early 2015, fans will have a chance to see ... America. Twenty-one-year-old Ariana Grande will hit the road in February ... 25 cities across the United States and Canada. Grande, the ...
(Date:9/20/2014)... 2014 The excitement is building up once again ... Carolina. This year the Surry Arts Council will be celebrating ... the country who are still fans of the Andy Griffith Show. ... that aired on CBS from 1960 through 1968. The show ... television history. Mount Airy, North Carolina is where the show ...
Breaking Medicine News(10 mins):Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 2Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 3Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Getting ‘Wellthy’: Mediaplanet’s “Work-Life Wellness” campaign puts stock in the personal and economic gains of healthy, vital workplace environments for Canadians 2Health News:Ariana Grande Tickets in New York, Philadelphia, Orlando, Fairfax, Worcester, Toronto, Uncasville, Detroit, Miami, Pittsburgh, Cleveland, and Atlanta On Sale Today 2Health News:Ariana Grande Tickets in New York, Philadelphia, Orlando, Fairfax, Worcester, Toronto, Uncasville, Detroit, Miami, Pittsburgh, Cleveland, and Atlanta On Sale Today 3Health News:Mayberry Days Parade Cars will be Provided by Mount Airy Toyota and Mount Airy Chrysler Dodge Jeep Ram 2
... Now Available at Sunrise Communities and Online -MCLEAN, Va. ... SRZ ) now offers a new informational guide to ... senior care in today,s challenging economy. The guide, ... is available at Sunrise communities nationwide and also online ...
... The American Dietetic Association will pursue a broad agenda ... Congress that a primary goal of new legislation should be ... should improve as a result of our health policy choices," ... needs to rise as a national priority, as it ties ...
... Enterprises to Capture and Automate Faxes to Enhance Productivity and Facilitate ... ... 2009 -- FaxBack® , the high-density VoIP fax leader for ... Machine Integration Server , an easy-to-install plug-in that turns fax machines ...
... rank low as risk factor, study finds , , MONDAY, ... not a predictor of future violent behavior, but mental ... the risk, according to U.S. researchers who analyzed data ... a severe mental illness but no substance abuse or ...
... drug vigabatrin (VGB) has been shown to be one of ... infants, called infantile spasm. However, its use has been limited ... a permanent narrowing of visual fields in approximately 40 percent ... later. A new study published in Epilepsia examined ...
... COLUMBUS, Ga., Feb. 2 Aflac Incorporated today,reported its fourth ... from the strengthening of the yen to the dollar,in the ... billion,in the fourth quarter of 2007. Net earnings were ... or $.78 per share, a year ago. , ...
Cached Medicine News:Health News:Sunrise Senior Living Helps Families Explore Senior Care Financing Options with New Guide 2Health News:American Dietetic Association Announces Agenda for Health Reform 2Health News:FaxBack Enables Fax Machine Integration With Document Management Systems 2Health News:FaxBack Enables Fax Machine Integration With Document Management Systems 3Health News:Mental Illness Doesn't Predict Violent Behavior 2Health News:Controversial medication may decrease spasms for infants with epilepsy 2Health News:Aflac Incorporated Announces Fourth Quarter Results, Sees 2008 RBC Ratio Above 450%, Affirms 2009 Operating EPS Target 2Health News:Aflac Incorporated Announces Fourth Quarter Results, Sees 2008 RBC Ratio Above 450%, Affirms 2009 Operating EPS Target 3Health News:Aflac Incorporated Announces Fourth Quarter Results, Sees 2008 RBC Ratio Above 450%, Affirms 2009 Operating EPS Target 4Health News:Aflac Incorporated Announces Fourth Quarter Results, Sees 2008 RBC Ratio Above 450%, Affirms 2009 Operating EPS Target 5Health News:Aflac Incorporated Announces Fourth Quarter Results, Sees 2008 RBC Ratio Above 450%, Affirms 2009 Operating EPS Target 6Health News:Aflac Incorporated Announces Fourth Quarter Results, Sees 2008 RBC Ratio Above 450%, Affirms 2009 Operating EPS Target 7Health News:Aflac Incorporated Announces Fourth Quarter Results, Sees 2008 RBC Ratio Above 450%, Affirms 2009 Operating EPS Target 8Health News:Aflac Incorporated Announces Fourth Quarter Results, Sees 2008 RBC Ratio Above 450%, Affirms 2009 Operating EPS Target 9Health News:Aflac Incorporated Announces Fourth Quarter Results, Sees 2008 RBC Ratio Above 450%, Affirms 2009 Operating EPS Target 10Health News:Aflac Incorporated Announces Fourth Quarter Results, Sees 2008 RBC Ratio Above 450%, Affirms 2009 Operating EPS Target 11Health News:Aflac Incorporated Announces Fourth Quarter Results, Sees 2008 RBC Ratio Above 450%, Affirms 2009 Operating EPS Target 12Health News:Aflac Incorporated Announces Fourth Quarter Results, Sees 2008 RBC Ratio Above 450%, Affirms 2009 Operating EPS Target 13Health News:Aflac Incorporated Announces Fourth Quarter Results, Sees 2008 RBC Ratio Above 450%, Affirms 2009 Operating EPS Target 14Health News:Aflac Incorporated Announces Fourth Quarter Results, Sees 2008 RBC Ratio Above 450%, Affirms 2009 Operating EPS Target 15
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: